• Sales rose to over EUR 71.0 m in the instrument business
• Operating profit (EBIT) increased by 34.0 % to EUR 6.3 m
• Earnings per share negatively impacted by increased income tax rate

Jena, November 10, 2009 — Analytik Jena AG (Frankfurt DE0005213508, Prime Standard: AJA) was still in line to achieve its main target in the 2008/2009 financial year and continued to enjoy strong growth despite the difficult overall economic climate. This was the announcement made by the Company today at the German Equity Conference held in Frankfurt am Main.

Over the past 2008/2009 financial year, the analytical, bioanalytical and optical systems and applications manufacturer achieved sales of EUR 71.2 m (previous year: EUR 53.1 m) in its instrument business. The Company therefore posted sales growth of 34.1 % in its core business, including the acquired subsidiaries CyBio AG and Biometra GmbH. Organic growth alone stood at 10.3 %. In the segments analytical solutions and bio solutions, Analytik Jena gained significant ground, whilst sales in optical solutions were down year-on-year.

Operating profit (EBIT) increased by 34.0 % to EUR 6.3 m (previous year: EUR 4.7 m), which corresponds to an EBIT margin of 8.9 %. Earnings before taxes (EBT) rose from EUR 2.9 m in the previous year to expectedly more than EUR 4.0 m in this period.

Also the operating cash flow with nearly EUR 6.0 m compared with the negative value of EUR -1.7 m in the previous year was developing positively.

For earnings per share the Company cannot report any resilient figures so far. This is attributable to tax burden by subsidiaries abroad that need to be audited yet. An increased income tax compared with the previous year is expected, so earnings per share will probably be close to the previous year's result.

Considering the consolidating global economy and the positive industry forecasts, Analytik Jena expects to continue its positive development and its overall growth.

The figures given in the announcement are preliminary figures. The final results for the 2008/2009 financial year (as of September 30) will be announced by the Group on December 17, 2009.

Contact:
Dana Schmidt
Analytik Jena AG
Konrad-Zuse-Strasse 1
07740 Jena  | Germany
Phone: +49 (0) 36 41  77-92 81
E-mail: ir@analytik-jena.com

• Well-known player in the growing market segment substantially strengthens life sciences portfolio of Analytik Jena
• Innovative products of Analytik Jena meet a well-positioned worldwide distribution network in over 60 countries

Jena / Goettingen, 30 April 2009 - Analytik Jena AG (Frankfurt, Prime Standard: AJA), a manufacturer and distributor of analytical and bioanalytical systems for industrial and scientific applications, today announced signing of deal for the acquisition of Biometra GmbH.

Biometra develops and provides innovative products in the broad field of thermo-cycling, electrophoresis, blotting, gel imaging and hybridization. The company was founded in 1985 and is one of the pioneers in the field of DNA polymerase chain reaction (PCR) technology. The Biometra PCR instruments are well positioned worldwide. Sales in recent years have been steady around 9.0 million EUR with good profitability. The integration of Biometra increases the competence of Analytik Jena in the field of DNA analysis through additional new technologies, and significantly strengthens the distribution structure. As a company with a longstanding tradition Biometra has a well-established distribution network. Through the acquisition Analytik Jena boosts its presence especially in Asia and Europe. In addition, it increases the direct distribution channels in the home market of Germany. Biometra has 55 employees.

Analytik Jena will acquire 100%of the shares of Biometra GmbH on 11.05.2009, based on an all cash transaction. The shares will be acquired from Whatman GmbH. Financial terms were not disclosed.

The product portfolios of the two companies are complementary. Analytik Jena also develops and distributes products for thermocycling, under a patented process, which enables an extremely rapid DNA reproduction. This is also true for other products, such as DNA-kits, DNA-chip Photometer, gel electrophoresis or gel-documentation. Hence, further innovative product developments can be optimized and faster implemented. Those synergies strengthen and accelerate the development of further innovative products.

Contact:
Dr. Mario Voigt
Analytik Jena AG
Konrad-Zuse-Strasse 1
07745 Jena | Germany
Phone +49 (0) 36 41  77-92 81
E-mail: ir@analytik-jena.com

Jena, February 23, 2009 – On Friday, February 20, 2009 at 8:00 p.m., Analytik Jena AG, Jena (ISIN DE 000 521 350 8) acquired a total of 2,467.950 shares in Cybio AG, Jena (ISIN DE 000 541 230 8). Analytik Jena AG had already acquired 296,050 shares in Cybio AG on February 19, 2009. Analytik Jena AG thus owns a total of 2,764,000 shares in Cybio AG, a 51.19 % holding in the share capital of Cybio AG. Analytik Jena AG has therefore acquired control of Cybio AG.

Contact:
Dr. Mario Voigt
Analytik Jena AG
Konrad-Zuse-Strasse 1
07745 Jena | Germany
Tel.: +49 (0) 36 41  77-92 81
E-mail: ir@analytik-jena.com

Financing additional growth in light of continuing positive business trends

Jena, January 29, 2009 — Analytik Jena AG (ISIN DE 000 521 3508) is planning to place up to 395,000 shares from a capital increase. On January 28, 2009, the Analytik Jena AG Executive Board resolved to increase the company's share capital based on authorization granted by the Annual General Meeting on March 21, 2007. The Supervisory Board gave its approval today. The capital increase will occur in accordance to the authorization resolution of the Annual General Meeting with shareholders' subscription rights disapplied. Analytik Jena mandated Bankhaus Neelmeyer to manage the transaction.

An issue amount of EUR 6.32 per share was determined. The new shares will be placed at bm-t beteiligungsmanagement thüringen gmbh, a company that already holds a sizable share package in Analytik Jena AG. By increasing its holdings, and thereby its commitment, the company ensures that the capital structure of Analytik Jena made up of both commercial and private investors remains robust. The proceeds from the capital increase will help to finance the company's further growth, particularly its activities in the Asian market and in the biotech industry.

Contact:
Dr. Mario Voigt
Analytik Jena AG
Konrad-Zuse-Strasse 1
07745 Jena | Germany
Tel. + 49 (0) 36 41  77-92 81
E-mail: ir@analytik-jena.com